Poster Presentations: Tuesday, October 25, 2011 |

Long-term Effects of Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) on Patient-Reported Outcomes and Health-care Utilization in African-American Patients With Asthma FREE TO VIEW

Randall Brown, MD; Christopher O'Brien, MD; Ubaldo Martin, MD; Tom Uryniak, MS; Kathy Lampl, MD
Chest. 2011;140(4_MeetingAbstracts):237A. doi:10.1378/chest.1117486
Text Size: A A A
Published online


PURPOSE: There is a paucity of information regarding response to inhaled corticosteroid (ICS)/long-acting β2-adrenergic agonist versus ICS in African Americans. Long-term effects on patient-reported outcomes and healthcare utilization with BUD/FM pMDI versus BUD pMDI were assessed as secondary end points in self-reported African-American patients with moderate to severe asthma.

METHODS: This randomized, double-blind, parallel-group, 1-year multicenter study (NCT00419952) included self-reported African-American patients aged ≥12 years with a diagnosis of asthma for ≥6 months. After a 2-week run-in on BUD pMDI 320 μg twice daily (bid), 742 patients were randomized 1:1 to receive BUD/FM pMDI 320/9 μg bid or BUD pMDI 320 μg bid.

RESULTS: The reduction in rescue medication use from baseline to the mean over the 1-year treatment period was greater with BUD/FM versus BUD (-0.52 vs -0.29 inhalations/day; unadjusted P=.003). Improvements were greater with BUD/FM versus BUD for percentage of rescue medication-free days (15.9% vs 10.6%; unadjusted P=.003) and asthma control days (16.7% vs 11.6%; unadjusted P=.006). Improvements in symptom-free days were similar with BUD/FM and BUD (9.5% vs 7.6%; unadjusted P=.178). Asthma-related resource utilization (number per patient-treatment year) was lower with BUD/FM versus BUD for unscheduled physician visits (0.08 vs 0.13; unadjusted P=.014), emergency department visits (0.03 vs 0.07; unadjusted P<.001), urgent care clinic visits (0.01 vs 0.04; unadjusted P<.001), and days of adjunctive asthma medication use (0.39 vs 1.78; unadjusted P<.001). Number of unscheduled phone calls to physicians per patient-treatment year was similar between treatments (0.42 for BUD/FM and 0.48 for BUD; unadjusted P=.461). No patients in the BUD/FM group and 4 patients in the BUD group experienced ≥1 hospitalization due to asthma (unadjusted P=.041).

CONCLUSIONS: BUD/FM pMDI 320/9 μg bid improved patient-reported outcomes and decreased healthcare utilization versus BUD pMDI 320 μg bid over 1 year in African-American patients with moderate to severe persistent asthma.

CLINICAL IMPLICATIONS: These findings support the use of BUD/FM pMDI in African-American patients with moderate to severe asthma.

DISCLOSURE: Randall Brown: Consultant fee, speaker bureau, advisory committee, etc.: Merck & Company, Inc; Teva Pharmaceuticals, LTD, Grant monies (from industry related sources): AstraZeneca LP

Christopher O'Brien: Shareholder: AstraZeneca LP, Employee: AstraZeneca LP

Ubaldo Martin: Employee: AstraZeneca LP, Shareholder: AstraZeneca LP

Tom Uryniak: Employee: AstraZeneca LP, Shareholder: AstraZeneca LP

Kathy Lampl: Employee: AstraZeneca LP, Shareholder: AstraZeneca LP

No Product/Research Disclosure Information

09:00 AM - 10:00 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543